<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>Biopharma News Feed - Immunology</title><link>https://nrouizem.github.io/test/immunology_feed.xml</link><description>Daily curated &amp; AI-summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/immunology_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Sat, 08 Mar 2025 01:06:22 +0000</lastBuildDate><item><title>Redefining vaccine trial recruitment</title><link>https://www.fiercebiotech.com/resource/redefining-vaccine-trial-recruitment</link><description>The article discusses the importance of addressing recruitment challenges and promoting diversity in vaccine clinical trials, emphasizing Avacare Clinical Research Network's new white paper on data-driven strategies to enhance trial efficiency and participant diversity. It does not mention any business deals, partnerships, mergers, or acquisitions, instead focusing on disseminating insights for optimizing trial recruitment practices.</description><pubDate>Wed, 26 Feb 2025 14:26:35 +0000</pubDate></item><item><title>Solutions for CAR-Engineered Cell Characterization</title><link>https://www.fiercebiotech.com/resource/solutions-car-engineered-cell-characterization</link><description>Cell Signaling Technology (CST) offers purpose-built tools, including recombinant antibodies targeting scFv linkers, to streamline CAR-engineered cell characterization and accelerate CAR development. These tools eliminate the need for costly anti-idiotype antibody development, simplifying workflows and reducing time and resource investments in the characterization process.</description><pubDate>Wed, 26 Feb 2025 14:49:25 +0000</pubDate></item></channel></rss>
